Has Bernice Robinson Bennett, MD received payments from drug or device companies?

Yes. Drug and device makers reported $927 in general payments to Bernice Robinson Bennett, MD across 27 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Bernice Robinson Bennett, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Bernice Robinson Bennett, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Bernice Robinson Bennett, MD

Gynecologic Oncology · West Reading, PANPI 1851453112

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $827 of the $927 with a category attached, or 89.2%. 7 manufacturers reported payments, led by GSK at 35.9% of the total. That places this record below the midpoint for gynecologic oncology clinicians in PA, where the typical reported total is $1,148.

$927in general payments, 2019–2025

Across 27 payments — averaging $34.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

GSK$333
Incyte Corporation$219
Eisai Inc.$115
Genmab U.S., Inc.$87
AbbVie$84
AstraZeneca$52
plus $37 from 1 others

What the payments were for

Food & beverage$82789%
Education$10011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
GSK	3	$333
Incyte Corporation	8	$219
Eisai Inc.	5	$115
Genmab U.S., Inc.	4	$87
AbbVie	3	$84
AstraZeneca	2	$52
Merck	2	$37

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ZEJULA$124
JEMPERLI$110

How this compares

$927 in reported general payments places this provider in the 45th percentile of 90 gynecologic oncology providers in Pennsylvania.

See all gynecologic oncology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$33,715

Medicare patients

159

Services billed

326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ZejulaNiraparib Tosylate	21	$356,881
Enoxaparin Sodium	15	$2,592
Anastrozole	40	$709
Letrozole	24	$506
Imiquimod	25	$474
Clobetasol Propionate	13	$315
Prochlorperazine Maleate	26	$150
Dexamethasone	36	$114
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	18	$100
Ondansetron OdtOndansetron	11	$97
Ondansetron Hcl	14	$37

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
GSKZejula	$333	$356,88121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 90 gynecologic oncology providers in Pennsylvania.